Biogen Idec’s Baminercept Alfa Shows Promise In Patients With Rheumatoid Arthritis

Biogen Idec presented data on baminercept alfa (BG9924, LTßR-Ig), the first dual-mechanism, lymphotoxin-ß; (LT-ß;) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases, including rheumatoid arthritis (RA), during the 2008 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology at the Le Palais de Congrés de Paris.

More: continued here

Filed under: Arthritis on June 17th, 2008